The overall safety and benefits of using nasal saline irrigations on viral upper respiratory infections during a pandemic, such as COVID-19, are discussed in this Viewpoint.
While the history and physical examination is important, only a few key signs and symptoms significantly change the underlying likelihood of community-acquired pneumonia (CAP).
Researchers at The Rockefeller University in New York have developed new tools to rapidly test the ability of antibodies to neutralize SARS-CoV-2, the novel coronavirus responsible for the COVID-19 pandemic. The approach, described today in the Journal of Experimental Medicine (JEM), will help researchers understand whether patients are susceptible to reinfection by SARS-CoV-2 and assess the effectiveness of experimental vaccines, as well as develop antibody-based therapies against the disease.
A series of autopsies conducted by LSU Health New Orleans pathologists shows the damage to the hearts of COVID-19 patients is not the expected typical inflammation of the heart muscle associated with myocarditis, but rather a unique pattern of cell death in scattered individual heart muscle cells.
International guidelines for asthma treatment recommend clinicians find the minimum effective dose that can control symptoms, yet asthma patients are increasingly prescribed high doses of medication. A study published in PLOS Medicine by Dr. Chloe Bloom at Imperial College London, United Kingdom and colleagues found that stepping-down medication doses did not increase asthma exacerbations and could significantly reduce medication costs.
In a collaboration among physicians at Beth Israel Deaconess Medical Center and Columbia University Irving Medical Center, researcher-clinicians have conducted an extensive review of the latest findings on COVID-19's effect on organ systems outside the lungs. Their review, published in Nature Medicine, also summarized proposed mechanisms behind these wide-ranging systemic effects and provided clinical guidance for physicians.
A replicating RNA vaccine, formulated with a lipid-based nanoparticle emulsion, produces antibodies against the COVID-19 coronavirus in mice and primates with a single immunization. These antibodies potently neutralize the virus in young and old animals. The antibody levels induced are comparable to those in recovered COVID-19 patients. This formulation is shelf-stable, with mass-production and distribution advantages.
An Online First Accepted Manuscript published in ARRS' American Journal of Roentgenology (AJR) finds that focusing on lung cancer screening (LCS) subjects less likely to remain in the program -- those with negative low-dose CT exams and those who still smoke -- can improve that program's cost-effectiveness and maximize its societal benefits. 'Our study demonstrates that a real-world LCS can perform similar to randomized controlled trials in regard to important performance metrics,' the authors of this AJR article conclude.
Cannabidiol, or CBD, may help reduce the cytokine storm and excessive lung inflammation that is killing many patients with COVID-19, researchers say.
An American Thoracic Society-led international task force has released a guidance document to help guide clinicians on restoring elective in-person pulmonary and sleep services as COVID-19 incidence decreases in their communities. The new guidance, published online in the Annals of the American Thoracic Society, is titled "Restoring Pulmonary and Sleep Services as the COVID-19 Pandemic Lessens."